| 產(chǎn)品名稱(chēng) |
Mumps rubulavirus |
| 商品貨號 |
B163025 |
| Classification |
Paramyxoviridae, Rubulavirus |
| Deposited As |
Mumps |
| Agent |
Mumps rubulavirus |
| Strain |
Enders |
| Common Name |
Mumps virus |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen |
| Storage Conditions |
-70°C or colder |
| Comments |
Same strain as VR-106. Adapted at CDC to grow in continuous cell line NCI-H292 (HuT-292)--see Castells et al. Arch Virol. 115:277-288, 1990. After adsorbing virus, feed with medium containing trypsin but NO serum. |
| Effect on Host |
Cytopathic effects in tissue culture. No CPE or extremely subtle CPE, cells thicken and some clumping. Hemadsorption and hemagglutination with chicken or guinea pig red blood cells. |
| Recommended Host |
NCI-H292 (ATCC® CRL-1848™) |
| Growth Conditions |
Temperature: 36°C
Atmosphere: 5% CO2 in air recommended
Incubation: 6 to 12 days at 36°C rocking, a 5% CO2 in air atmosphere is recommended.
Recommendations for Infection: For best results cells should be 48 to 72 hours old and 100% confluent. |
| Name of Depositor |
JC Hierholzer |
| Source |
Pooled saliva from patients, Massachusetts |
| References |
Enders JF, et al. Immunity in mumps: I. Experiments with monkeys (Macacus mulatta). The development of complement-fixing antibody following infection and experiments on immunization by means of inactivated virus and convalescent human serum. J. Exp. Med. 81: 93-117, 1945. PubMed: 19871448.
Levens JH, Enders JF. . Science 102: 117, 1945.
|
